Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8439728 | 0.88 | PDE5A (0.31) | TDP1CA2 | |
| SCHEMBL436664 | 0.74 | — | — | |
| SCHEMBL8037603 | 0.74 | — | — | |
| SCHEMBL7038729 | 0.74 | — | — | |
| SCHEMBL8039068 | 0.74 | — | — | |
| SCHEMBL3533840 | 0.74 | — | — | |
| SCHEMBL8644300 | 0.74 | — | — | |
| SCHEMBL8440434 | 0.72 | BACE1 (0.38) | — | |
| SCHEMBL11447658 | 0.71 | LPL (0.31) | — | |
| SCHEMBL39411 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117864-A1 | POLYCARBONATE COPOLYMER COMPRISING UNITS DERIVED FROM ANHYDROSUGAR ALCOHOL, AROMATIC DIOL, AND HYDROXY-TERMINATED SILOXANE, METHOD FOR PRODUCING SAME, AND MOLDED ARTICLE COMPRISING SAME | 주식회사 삼양사 | 2024-06-06 | — | — | WO | disclosed |
| WO-2024095968-A1 | OPTICAL FILM | 大倉工業株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024071233-A1 | OPTICAL FILM | 大倉工業株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2023121395-A1 | BIODEGRADABLE POLYCARBONATE COPOLYMER COMPRISING UNITS DERIVED FROM ANHYDROSUGAR ALCOHOL, ANHYDROSUGAR ALCOHOL-ALKYLENE GLYCOL, AND AROMATIC DIOL, METHOD FOR PRODUCING SAME, AND MOLDED PRODUCT COMPRISING SAME | 주식회사 삼양사 | 2023-06-29 | — | — | WO | disclosed |
| EP-1778243-B1 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1778243-B1 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-5998433-A | THERAPY FOR HYPERLIPIDEMIA; ATHEROSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0785939-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011201-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| EP-0651732-A1 | EMULSIFIED FURAN RESIN BASED GLASS FIBER BINDING COMPOSITIONS AND PROCESS OF BINDING GLASS FIBERS | Schuller International, Inc. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994026677-A1 | EMULSIFIED FURAN RESIN BASED GLASS FIBER BINDING COMPOSITIONS AND PROCESS OF BINDING GLASS FIBERS | SCHULLER INTERNATIONAL, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | HTR5A, HTR4, HTR7 | TDP1 2836/4885CA2 4609/4885 |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | TDP1 3140/4885CA2 1067/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | TDP1 3140/4885CA2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.